摘要
肿瘤治疗在循证医学的基础上逐渐向循因医学过渡,肿瘤个体化治疗已成为肿瘤治疗的发展方向。肿瘤患者对各种化疗药物存在明显的个体差异,其主要原因是患者个体肿瘤相关基因表达的差异和多态性。代谢组学的出现和发展有效地解决了传统检查手段的不足,利用代谢组学技术在肿瘤患者的组织、血液和尿液等物质中检测代谢产物,寻找差异性的代谢产物,发现新的特异性的肿瘤标志物,在其诊断和治疗上有很大优势。代谢组学在结直肠癌诊断中的应用提示了代谢组学在肿瘤患者的个体化治疗中已经越来越重要。
Treatment of tumor based on evidence-based medicine gradually becomes mechanism-based medicine. Personalized cancer therapy has become the direction. Tumor patients have obvious individual differences toward various chemotherapeutic drugs. The main reason is the difference in tumor related gene expression and polymorphism. The advent and development of metabolomics effectively overcomes shortcomings of traditional examination methods. It has great advantage in the detection of metabolites intumor tissue, blood and urine, looking for metabolite differences and finding new and specific tumor marker. This paper summarizes the application of metabonomics in the diagnosis of colorectal cancer. It shows that metabonomics for treating individual cancer patients has become more and more important.
出处
《长春中医药大学学报》
2014年第3期520-523,共4页
Journal of Changchun University of Chinese Medicine
基金
浙江省自然基金项目"基于代谢组学的Ⅲ~Ⅳ期结直肠癌气虚证患者肠道微生态变化及预后相关生物标志物筛选"(LY13H270011)
作者简介
戚益铭（1989-），男，硕士研究生。研究方向：中医肿瘤。
[通信作者]沈敏鹤，电话：18814881412，电子信箱：shenminhe@aliyun．com
